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The two clinical research sessions considered the status of
previous trials, as examined in the Oxford Overview
(Professsor Ingle) [1], as a background for the discussion of
the current generation of clinical trials employing endocrine
therapy and other targeted therapies (Professor Hudis) [2].
Clinical outcomes were considered within the context of the
spectrum of clinical trials (Professor Cameron) [3], and the
concluding presentation addressed a novel paradigm for
future research (Professor Howell) [4].
Professor James Ingle [1] addressed the findings of the most
recent main meeting of the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) from September 2006.
Updated information from this Oxford Overview addresses
the value of systemic therapy (tamoxifen, ovarian oblation/
suppression, polychemotherapy, anthracyclines, aromatase
inhibitors, taxanes and high-dose chemotherapy) and local
therapy (postmastectomy radiation therapy). All of these
analyses will be the subject of reports in the near future from
the EBCTCG. The Oxford Overview process was initiated in
the era of relatively small and underpowered clinical trials,
and the resulting meta-analyses revealed robust information
that would otherwise not have been available. The meeting
attendees addressed the question of the relevance of the
Oxford Overview process in the era of very large clinical trials
as are being conducted today. The conclusion was that the
Oxford Overview remains highly relevant and is a mechanism
to gain knowledge relating to end-points, such as survival and
adverse events, which cannot readily be obtained from
individual trials despite their large size.
Professor Cliff Hudis [2] addressed the very important area of
combined endocrine therapy and other targeted therapies.
The primary goal of this research is to address endocrine
therapy resistance in the cancer cell. The crosstalk between
the oestrogen receptor pathway and growth factor pathways,
such as the HER pathways, is a prime example of ongoing
research. Numerous potential targets exist, including
downstream signalling mediators, angiogenesis and cyclo-
oxygenase-2. Of great importance and opportunity in
targeted therapy research is the availability of the specific
targets for interrogation in clinical trials. The acquisition of
biological information in clinical research is an important goal
of current and future research.
Professor David Cameron [3] addressed the important
questions of surrogate end-points in clinical trials. Whereas
overall survival is the ultimate end-point, the case is made for
utilizing other end-points according to the stage of disease
and needs of the patient, for example utilizing disease-free
survival as the first end-point in the adjuvant trial because of
its relationship to overall survival. Important consideration in
surrogate end-points is the use of biological factors that can
be examined in short-term therapy studies and thus related to
long-term outcome of patients. This will remain a crucial area
of future research.
Professor Anthony Howell considered metabolic approaches
to breast cancer therapy and prevention as a paradigm for
future research. This provocative discussion provided
evidence of and support for targeting metabolic pathways
either alone or in combination with standard therapies. Of
particular interest are the data on new agents that mimic
caloric restriction, called caloric restriction mimetics. This
novel approach provides a new area of investigation based on
our increasing understanding of metabolic pathways in
tumours.
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